Cargando…

SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model

OBJECTIVES: We investigated the efficacy of the novel antimicrobial agent SMT19969 in treating simulated Clostridium difficile infection using an in vitro human gut model. METHODS: Concentrations of the predominant cultivable members of the indigenous gut microfloras and C. difficile (total and spor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baines, S. D., Crowther, G. S., Freeman, J., Todhunter, S., Vickers, R., Wilcox, M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267497/ https://www.ncbi.nlm.nih.gov/pubmed/25190720 http://dx.doi.org/10.1093/jac/dku324

Ejemplares similares

In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile
por: Corbett, D., et al.
Publicado: (2015)

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
por: Freeman, Jane, et al.
Publicado: (2015)

In Vivo Assessment of SMT19969 in a Hamster Model of Clostridium difficile Infection
por: Weiss, William, et al.
Publicado: (2014)

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI
por: Sattar, Abdul, et al.
Publicado: (2015)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections
por: Vickers, Richard, et al.
Publicado: (2015)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
por: Goldstein, Ellie J. C., et al.
Publicado: (2014)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota
por: Crowther, Grace S., et al.
Publicado: (2014)

Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection
por: Baines, Simon D., et al.
Publicado: (2015)

Comparison of Supplemented Brucella Agar and Modified Clostridium difficile Agar for Antimicrobial Susceptibility Testing of Clostridium difficile
por: Kim, Gye Hyeong, et al.
Publicado: (2014)

Antimicrobial susceptibility of Clostridium difficile isolated in Thailand
por: Putsathit, Papanin, et al.
Publicado: (2017)

Antimicrobial Susceptibility of Clostridium Difficile Clinical Isolates in Iran
por: Goudarzi, Mehdi, et al.
Publicado: (2013)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm
por: Crowther, Grace S, et al.
Publicado: (2015)

Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
por: Mihajlov, Kiril, et al.
Publicado: (2019)

Role of cephalosporins in the era of Clostridium difficile infection
por: Wilcox, Mark H., et al.
Publicado: (2017)

Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection
por: Vincent, Caroline, et al.
Publicado: (2015)

Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection
por: Chilton, C. H., et al.
Publicado: (2016)

Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078
por: Keessen, Elisabeth C, et al.
Publicado: (2013)

Prevalence and antimicrobial susceptibility pattern of toxigenic Clostridium difficile strains isolated in Iran
por: MOHAMMADBEIGI, Maryam, et al.
Publicado: (2019)

2372. PCR Ribotype and Antimicrobial Susceptibility of Clostridioides (Formerly Clostridium) difficile in Korea
por: Hoo Jeon, Cheon, et al.
Publicado: (2019)

Genotyping and Antimicrobial Susceptibility of Clostridium perfringens and Clostridioides difficile in Camel Minced Meat
por: Fayez, Mahmoud, et al.
Publicado: (2021)

SMT soldering handbook
por: Strauss, Rudolf, et al.
Publicado: (1998)

Sensitivity of Single-Molecule Array Assays for Detection of Clostridium difficile Toxins in Comparison to Conventional Laboratory Testing Algorithms
por: Banz, Alice, et al.
Publicado: (2018)

In Vitro Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
por: Freeman, Jane, et al.
Publicado: (2017)

MachSMT: A Machine Learning-based Algorithm Selector for SMT Solvers
por: Scott, Joseph, et al.
Publicado: (2021)

Short-Term Genome Stability of Serial Clostridium difficile Ribotype 027 Isolates in an Experimental Gut Model and Recurrent Human Disease
por: Eyre, David W., et al.
Publicado: (2013)

Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from two Korean hospitals
por: Nicholas, Asiimwe, et al.
Publicado: (2017)

Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion
por: Fraga, Edmir Geraldo, et al.
Publicado: (2016)

Conventional and alternative treatment approaches for Clostridium difficile infection
por: Aljarallah, Khalid M.
Publicado: (2017)

Molecular Characterization and Moxifloxacin Susceptibility of Clostridium difficile
por: Mizrahi, Sarah, et al.
Publicado: (2019)

In vitro characterisation of Spontaneous Mammary Tumour (SMT1) cells and its matched lung metastatic (SMT1L) cells
por: Wong, TC, et al.
Publicado: (2012)

1344. Ridinilazole (RDZ) for Clostridium difficile Infection (CDI): Impact of Diagnostic Method on Outcomes From a Phase 2 Clinical Trial
por: Vickers, Richard, et al.
Publicado: (2018)

Clostridium difficile: moving beyond antimicrobial therapy
por: Adalja, Amesh A, et al.
Publicado: (2010)

The Antimicrobial Stewardship Approach to Combating Clostridium Difficile
por: Wenzler, Eric, et al.
Publicado: (2015)

Novel Antimicrobials for the Treatment of Clostridium difficile Infection
por: Petrosillo, Nicola, et al.
Publicado: (2018)

In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile
por: Lee, Joong-Su, et al.
Publicado: (2013)

Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection
por: Theriot, Casey M., et al.
Publicado: (2014)

Biofilm formation of Clostridium difficile and susceptibility to Manuka Honey
por: Hammond, Eric N, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8jip6ea4ofqlj09dc0a6mlu6qs